1. |
TRAVIS R C, KEY T J. Oestrogen exposure and breast cancer risk[J]. Breast Cancer Res,2003,5(5):239-247..
|
2. |
PIKE M C, SPICER D V, DAHMOUSH L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk[J]. Epidemiol Rev,1993,15(1):17-20..
|
3. |
杨才明, 夏淑君.HER2 2/neu基因蛋白、BRCA1和BRCA2基因突变检测在乳腺癌诊断和治疗中的临床意义[J].标记免疫分析与临床,2005,12(1):43-45..
|
4. |
WILEY S R, SCHOOLEY K, SMOLAK P J, et al. Indentification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity,1995,3(6):673-682..
|
5. |
ASHKENAZI A, PAI R C, FONG S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[J]. J Clin Invest,1999,104(2):155-162..
|
6. |
张玉松,傅晋祥,周丽英,等.肿瘤坏死因子相关凋亡诱导配体与赫赛汀联用对C-erbB2过表达的乳腺癌SKBR3细胞株的影响[J]. 苏州大学学报,2007,27(1):38-40..
|
7. |
YAGER J D, DAVIDSON N E. Estrogen carcinogenesis in breast cancer[J]. N Engl J Med,2006,354:270-282..
|
8. |
SAUNDERS P T, MILLAR M R, WILLIAMS K, et al. Expression of oestrogen receptor β (ERβ1) protein in human breast cancer biopsies[J]. Br J Cancer,2002,86(2):250-256..
|
9. |
朱冉旭, 林菊生.死亡受体DR5与肿瘤细胞凋亡[J].世界华人消化杂志,2004,12(8):1909-1912.
|
10. |
马远方, 张军, 赵粤萍, 等.肿瘤细胞对TRAIL敏感性与其表面DR5表达水平的相关研究[J].中华肿瘤杂志,2004,26(9):528-530..
|
11. |
李妍,曹云新,张赟,等.IFN-α对肿瘤细胞上TRAIL受体 DR4 和DR5 表达的调节及意义[J].第四军医大学吉林军医学院学报,2005,26(1):7-10.
|